URSODEOXYCHOLATE AND METHOTREXATE FOR BILIARY CIRRHOSIS
$0M01FY2000RRNIH
University Of California San Francisco, San Francisco CA
Investigators
Linked publications & trials
Paper 32841311Paper 30917704Paper 30635658Paper 30571226Paper 29544657Paper 29479291Paper 28637271Paper 28353541Paper 28296798Paper 27546606Paper 27388144Paper 27382421Paper 26927006Paper 26106560Paper 26091977Paper 25918834Paper 25409471Paper 24959962Paper 24755714Paper 24702955Paper 24683513Paper 24615880Paper 24598797Paper 24570214Paper 24419071Paper 24367482Paper 24260137Paper 24220913Paper 24105030Paper 23954497Paper 23934991Paper 23904290Paper 23901097Paper 23874208Paper 23687224Paper 23649774Paper 23637325Paper 23614994Paper 23508266Paper 23468661Paper 23441606Paper 23441136Paper 23315317Paper 23287403Paper 23249952Paper 23242158Paper 23212606Paper 23175617Paper 23127215Paper 23124848Paper 23073395Paper 23070669Paper 23042117Paper 23023776Paper 22944874Paper 22904263Paper 22863642Paper 22862153Paper 22833143Paper 22707612Paper 22588883Paper 22549897Paper 22523428Paper 22476155Paper 22464253Paper 22436836Paper 22399793Paper 22231568Paper 22189356Paper 22174698Paper 22155768Paper 22110124Paper 22060063Paper 22029979Paper 22027585Paper 21999979Paper 21995304Paper 21991891Paper 21952918Paper 21881831Paper 21875343Paper 21871250Paper 21813792Paper 21768873Paper 21719445Paper 21712645Paper 21637784Paper 21637766Paper 21617528Paper 21614020Paper 21590681Paper 21584946Paper 21512513Paper 21463066Paper 21437871Paper 21430657Paper 21415358Paper 21408207Paper 21391124Paper 21382963
Abstract
The major thrust of this treatment study is to compare the effects of UDCA plus methotrexate versus UDCA plus placebo on the course of patients with primary biliary cirrhosis. The GCRC will be utilized in the collection of data via lab draws, monitoring of patients, post-liver biopsy, post endoscopy, and facilitating other required tests.
View original record on NIH RePORTER →